De Paula, Bruno
C Smyth, Elizabeth http://orcid.org/0000-0001-6427-229X
Article History
Received: 16 February 2021
Revised: 10 March 2021
Accepted: 16 March 2021
First Online: 30 April 2021
Ethics approval and consent to participate
: This manuscript is based on published data, therefore ethical approval and consent is not applicable.
: The data mentioned on this manuscript is fully available online. Any further information not provided should be discussed with the corresponding authors of each cited paper.
: Bruno de Paula declares personal consultancy fees and/or travel in the past 5 years from: Roche and Pfizer Elizabeth Smyth declares personal consultancy fees and/or travel in the past 5 years from: Aptitude Health, Astra Zeneca, BMS, Celgene, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Roche, Sai-Med, Servier, Zymeworks.
: There was no funding for this manuscript.